Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

AgeX Therapeutics, Inc. (AGE)

0.5705   -0.03 (-4.96%) 11-28 15:49
Open: 0.6 Pre. Close: 0.6003
High: 0.61 Low: 0.57
Volume: 28,970 Market Cap: 22(M)

Technical analysis

as of: 2022-11-28 4:37:44 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.74     One year: 0.8
Support: Support1: 0.55    Support2: 0.45
Resistance: Resistance1: 0.63    Resistance2: 0.68
Pivot: 0.61
Moving Average: MA(5): 0.59     MA(20): 0.61
MA(100): 0.63     MA(250): 0.71
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 29.5     %D(3): 38
RSI: RSI(14): 43.5
52-week: High: 1.38  Low: 0.51
Average Vol(K): 3-Month: 22 (K)  10-Days: 13 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AGE ] has closed above bottom band by 15.6%. Bollinger Bands are 9.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.6 - 0.6 0.6 - 0.61
Low: 0.56 - 0.57 0.57 - 0.57
Close: 0.57 - 0.57 0.57 - 0.58

Company Description

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.

Headline News

Mon, 28 Nov 2022
Virginia Rep. Donald McEachin dies at age 61 - CNN

Mon, 28 Nov 2022
Delegates at odds — proposal to lower voting age to 16 returns - WHSV

Mon, 28 Nov 2022
An analysis of COVID-19's dynamics, its impact on various age groups, anti-vaxxers and re-infection - News-Medical.Net

Mon, 28 Nov 2022
Slow cognitive decline with flavonols, study says - CNN

Mon, 28 Nov 2022
Musk says Apple has mostly stopped advertising on Twitter - AdAge.com

Mon, 28 Nov 2022
Our Brains Don’t Fully Develop Until We’re 25. What Does That Mean For Age Gap Relationships? - Refinery29

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 38 (M)
% Held by Insiders 1.845e+007 (%)
% Held by Institutions 43.4 (%)
Shares Short 309 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.93e+006
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -13
Return on Assets (ttm) 320.7
Return on Equity (ttm) -199
Qtrly Rev. Growth 53000
Gross Profit (p.s.) 0.04
Sales Per Share 0.04
EBITDA (p.s.) -0.23
Qtrly Earnings Growth -0.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -6 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 12.15
Price to Cash Flow -0

Stock Dividends

Dividend 0
Forward Dividend 303480
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.